Cypress Asset Management Inc. TX Takes Position in Becton, Dickinson and Company (NYSE:BDX)

Cypress Asset Management Inc. TX acquired a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 4,485 shares of the medical instruments supplier's stock, valued at approximately $1,094,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of BDX. MGO One Seven LLC grew its stake in Becton, Dickinson and Company by 33.8% during the 3rd quarter. MGO One Seven LLC now owns 1,926 shares of the medical instruments supplier's stock worth $498,000 after purchasing an additional 486 shares in the last quarter. Signaturefd LLC lifted its holdings in Becton, Dickinson and Company by 6.5% during the 3rd quarter. Signaturefd LLC now owns 2,782 shares of the medical instruments supplier's stock worth $719,000 after buying an additional 170 shares during the last quarter. Syon Capital LLC purchased a new stake in Becton, Dickinson and Company during the 3rd quarter worth about $343,000. NBC Securities Inc. purchased a new stake in Becton, Dickinson and Company during the 3rd quarter worth about $119,000. Finally, Pinnacle Financial Partners Inc purchased a new stake in Becton, Dickinson and Company during the 3rd quarter worth about $255,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of the company's stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $236.70, for a total transaction of $781,110.00. Following the completion of the sale, the executive vice president now directly owns 14,608 shares of the company's stock, valued at approximately $3,457,713.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the business's stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Roland Goette sold 3,300 shares of the business's stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $236.70, for a total value of $781,110.00. Following the transaction, the executive vice president now owns 14,608 shares in the company, valued at approximately $3,457,713.60. The disclosure for this sale can be found here. Insiders sold a total of 8,597 shares of company stock valued at $2,028,786 in the last ninety days. Insiders own 0.31% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Barclays lifted their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an "overweight" rating in a report on Monday, May 6th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $281.40.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock traded down $4.10 on Thursday, hitting $230.35. The stock had a trading volume of 1,302,585 shares, compared to its average volume of 1,412,302. Becton, Dickinson and Company has a 52-week low of $229.40 and a 52-week high of $287.32. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The stock has a market cap of $66.57 billion, a price-to-earnings ratio of 51.64, a P/E/G ratio of 2.06 and a beta of 0.45. The company's 50 day moving average price is $237.96 and its 200 day moving average price is $238.60.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same period in the previous year, the business earned $2.86 EPS. The business's quarterly revenue was up 4.6% on a year-over-year basis. On average, research analysts anticipate that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 1.65%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company's dividend payout ratio is presently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.